trial

Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

NCTId NCT01795183
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 316 (actual)
Sponsored by Sanofi
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
316 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-11
Primary completion
2013-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

SanofiLead Sponsor

Investigators

1
Clinical Sciences & OperationsStudy Director

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
316
Phase
PHASE4
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
Sanofi
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Sciences & Operations
person